» Articles » PMID: 21408213

Quantification of the Relative Importance of CTL, B Cell, NK Cell, and Target Cell Limitation in the Control of Primary SIV-infection

Overview
Specialty Biology
Date 2011 Mar 17
PMID 21408213
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, B cells and target cell limitation have all been suggested to play a role in the control of SIV and HIV-1 infection. However, previous research typically studied each population in isolation leaving the magnitude, relative importance and in vivo relevance of each effect unclear. Here we quantify the relative importance of CTLs, NK cells, B cells and target cell limitation in controlling acute SIV infection in rhesus macaques. Using three different methods, we find that the availability of target cells and CD8+ T cells are important predictors of viral load dynamics. If CTL are assumed to mediate this anti-viral effect via a lytic mechanism then we estimate that CTL killing is responsible for approximately 40% of productively infected cell death, the remaining cell death being attributable to intrinsic, immune (CD8+ T cell, NK cell, B cell) -independent mechanisms. Furthermore, we find that NK cells have little impact on the death rate of infected CD4+ cells and that their net impact is to increase viral load. We hypothesize that NK cells play a detrimental role in SIV infection, possibly by increasing T cell activation.

Citing Articles

Antiviral capacity of the early CD8 T-cell response is predictive of natural control of SIV infection: Learning in vivo dynamics using ex vivo data.

Vemparala B, Madelain V, Passaes C, Millet A, Avettand-Fenoel V, Djidjou-Demasse R PLoS Comput Biol. 2024; 20(9):e1012434.

PMID: 39255323 PMC: 11414924. DOI: 10.1371/journal.pcbi.1012434.


An Improved Two-Shot Tracking Algorithm for Dynamics Analysis of Natural Killer Cells in Tumor Contexts.

Zhou Y, Tang Y, Li Z Bioengineering (Basel). 2024; 11(6).

PMID: 38927775 PMC: 11200953. DOI: 10.3390/bioengineering11060540.


CD8 lymphocytes do not impact SIV reservoir establishment under ART.

Statzu M, Jin W, Fray E, Wong A, Kumar M, Ferrer E Nat Microbiol. 2023; 8(2):299-308.

PMID: 36690860 PMC: 9894752. DOI: 10.1038/s41564-022-01311-9.


Immune-Enhancing Effects of Co-treatment With Nakai Bark and Gaertner Leaf Extract in a Cyclophosphamide-Induced Immunosuppressed Rat Model.

Park Y, Lee H, Shin D, Kim D, Yoo J, Yang H Front Nutr. 2022; 9:898417.

PMID: 35662944 PMC: 9161550. DOI: 10.3389/fnut.2022.898417.


Immuno-enhancement effects of Platycodon grandiflorum extracts in splenocytes and a cyclophosphamide-induced immunosuppressed rat model.

Noh E, Kim J, Lee H, Song H, Joung S, Yang H BMC Complement Altern Med. 2019; 19(1):322.

PMID: 31752816 PMC: 6868875. DOI: 10.1186/s12906-019-2724-0.


References
1.
Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg E . HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol. 2009; 83(13):6798-805. PMC: 2698561. DOI: 10.1128/JVI.00256-09. View

2.
Gaufin T, Gautam R, Kasheta M, Ribeiro R, Ribka E, Barnes M . Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood. 2009; 113(18):4250-61. PMC: 2676085. DOI: 10.1182/blood-2008-09-177741. View

3.
OConnell K, Han Y, Williams T, Siliciano R, Blankson J . Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol. 2009; 83(10):5028-34. PMC: 2682110. DOI: 10.1128/JVI.02551-08. View

4.
Pantaleo G, Graziosi C, Fauci A . The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993; 328(5):327-35. DOI: 10.1056/NEJM199302043280508. View

5.
Brichacek B, Swindells S, Janoff E, Pirruccello S, Stevenson M . Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis. 1996; 174(6):1191-9. DOI: 10.1093/infdis/174.6.1191. View